Insider Trading Alert - CFN, MD, PNC, ITMN And PLCM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 5, 2014, 146 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.84 to $26,546,700.00.

Highlighted Stocks Traded by Insiders:

CareFusion (CFN) - FREE Research Report

Leonard Thomas J who is President, Medical Systems at CareFusion sold 21,496 shares at $38.24 on Feb. 5, 2014. Following this transaction, the President, Medical Systems owned 38,303 shares meaning that the stake was reduced by 35.95% with the 21,496-share transaction.

The shares most recently traded at $38.68, up $0.44, or 1.13% since the insider transaction. Historical insider transactions for CareFusion go as follows:

  • 4-Week # shares sold: 25,000
  • 12-Week # shares sold: 62,500
  • 24-Week # shares sold: 66,250

The average volume for CareFusion has been 1.6 million shares per day over the past 30 days. CareFusion has a market cap of $8.2 billion and is part of the health care sector and health services industry. Shares are down 3.26% year-to-date as of the close of trading on Wednesday.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. The company has a P/E ratio of 22.2. Currently there are 5 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFN - FREE

TheStreet Quant Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full CareFusion Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Mednax (MD) - FREE Research Report

Lopez-Blanco Vivian who is Chief Financial Officer at Mednax sold 9,200 shares at $55.20 on Feb. 5, 2014. Following this transaction, the Chief Financial Officer owned 64,148 shares meaning that the stake was reduced by 12.54% with the 9,200-share transaction.

The shares most recently traded at $55.00, down $0.20, or 0.36% since the insider transaction. Historical insider transactions for Mednax go as follows:

  • 12-Week # shares sold: 1,495
  • 24-Week # shares sold: 1,495

The average volume for Mednax has been 551,000 shares per day over the past 30 days. Mednax has a market cap of $5.4 billion and is part of the health care sector and health services industry. Shares are up 2% year-to-date as of the close of trading on Wednesday.

MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric subspecialties, and anesthesia care physician services in the United States and Puerto Rico. The company has a P/E ratio of 19.4. Currently there are 6 analysts that rate Mednax a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MD - FREE

TheStreet Quant Ratings rates Mednax as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Mednax Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PNC Financial Services Group (PNC) - FREE Research Report

Gulley Joan L who is EVP & Chief HR Officer at PNC Financial Services Group sold 2,000 shares at $79.88 on Feb. 5, 2014. Following this transaction, the EVP & Chief HR Officer owned 14,849 shares meaning that the stake was reduced by 11.87% with the 2,000-share transaction.

The shares most recently traded at $79.01, down $0.87, or 1.1% since the insider transaction. Historical insider transactions for PNC Financial Services Group go as follows:

  • 4-Week # shares sold: 16,018
  • 12-Week # shares sold: 20,018
  • 24-Week # shares sold: 26,018

The average volume for PNC Financial Services Group has been 2.3 million shares per day over the past 30 days. PNC Financial Services Group has a market cap of $42.0 billion and is part of the financial sector and banking industry. Shares are up 1.59% year-to-date as of the close of trading on Wednesday.

The PNC Financial Services Group, Inc. operates as a diversified financial services company in the United States and internationally. The company's Retail Banking segment provides deposit, lending, brokerage, investment management, and cash management services. The stock currently has a dividend yield of 2.23%. The company has a P/E ratio of 10.7. Currently there are 10 analysts that rate PNC Financial Services Group a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PNC - FREE

TheStreet Quant Ratings rates PNC Financial Services Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, expanding profit margins, impressive record of earnings per share growth and attractive valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full PNC Financial Services Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

InterMune (ITMN) - FREE Research Report

Welch Daniel G who is Chairman, CEO and President at InterMune sold 20,000 shares at $13.08 on Feb. 5, 2014. Following this transaction, the Chairman, CEO and President owned 117,434 shares meaning that the stake was reduced by 14.55% with the 20,000-share transaction.

The shares most recently traded at $11.34, down $1.74, or 15.34% since the insider transaction. Historical insider transactions for InterMune go as follows:

  • 4-Week # shares sold: 100,000
  • 12-Week # shares sold: 120,000
  • 24-Week # shares sold: 150,002

The average volume for InterMune has been 1.2 million shares per day over the past 30 days. InterMune has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are down 21.05% year-to-date as of the close of trading on Wednesday.

InterMune, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases. The company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Currently there are 9 analysts that rate InterMune a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITMN - FREE

TheStreet Quant Ratings rates InterMune as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full InterMune Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Polycom (PLCM) - FREE Research Report

Durr Laura who is SVP, Worldwide Finance at Polycom sold 2,877 shares at $11.54 on Feb. 5, 2014. Following this transaction, the SVP, Worldwide Finance owned 33,681 shares meaning that the stake was reduced by 7.87% with the 2,877-share transaction.

The shares most recently traded at $11.99, up $0.45, or 3.75% since the insider transaction. Historical insider transactions for Polycom go as follows:

  • 4-Week # shares sold: 30,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares sold: 40,940

The average volume for Polycom has been 2.2 million shares per day over the past 30 days. Polycom has a market cap of $1.7 billion and is part of the technology sector and telecommunications industry. Shares are up 4.01% year-to-date as of the close of trading on Wednesday.

Polycom, Inc. provides standards-based unified communications and collaboration (UC&C) solutions for voice and video collaboration. The company has a P/E ratio of 21.1. Currently there are 2 analysts that rate Polycom a buy, 2 analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PLCM - FREE

TheStreet Quant Ratings rates Polycom as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and weak operating cash flow. Get the full Polycom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know